Leber Hereditary Optic Neuropathy
10
3
3
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
20%
2 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (10)
Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year
Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients
REALITY LHON Registry
RESCUE and REVERSE Long-term Follow-up
New Non-invasive Modalities for Assessing Retinal Structure and Function
Metabolomics Analysis According to the Retinal Nerve Fiber Layer in Patients With NOHL Mutations (MétabOCT)
Stem Cell Ophthalmology Treatment Study II
A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy
Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON)
Trial of Cyclosporine in the Acute Phase of Leber Hereditary Optic Neuropathy